Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2

Prostate

Volumn 72, Issue 7, 2012, Pages 705-712

  Tomiá, Tajana Tešan ^a   Gustavsson, Heléne ^a   Wang, Wanzhong ^a   Jennbacken, Karin ^a   Welén, Karin ^a   Damber, Jan Erik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

androgen deprivation therapy; blood vessel morphology; hormone na ve; microvessel density; pericytes

Indexed keywords

ANGIOPOIETIN 2; ANTIANDROGEN; VASCULOTROPIN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLOOD ANALYSIS; BLOOD VESSEL; CANCER RELAPSE; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROTEIN EXPRESSION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANGIOPOIETIN-2; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; ORCHIECTOMY; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860340496     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21472     Document Type: Article

References (41)

1. Strohmeyer D, Rossing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S,. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 2000; 42 (1): 26-33. (Pubitemid 30004872)
2. Revelos K, Petraki C, Scorilas A, Stefanakis S, Malovrouvas D, Alevizopoulos N, Kanellis G, Halapas A, Koutsilieris M,. Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res 2007; 27 (5B): 3651-3660. (Pubitemid 47607515)
3. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J,. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143 (2): 401-409. (Pubitemid 24058195)
4. Lissbrant IF, Stattin P, Damber JE, Bergh A,. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 1997; 33 (1): 38-45. (Pubitemid 27381593)
5. Gustavsson H, Welen K, Damber JE,. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 2005; 62 (4): 364-373. (Pubitemid 40227488)
6. Kosaka T, Miyajima A, Takayama E, Kikuchi E, Nakashima J, Ohigashi T, Asano T, Sakamoto M, Okita H, Murai M, Hayakawa M,. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2007; 67 (1): 41-49. (Pubitemid 46013466)
7. Gustavsson HWW, Jennbacken K, Welén K, Damber JE,. ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer. BJU Int 2009; 104 (11): 1786-1790.
8. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi BZ,. Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 1994; 5 (1): 89-97.
9. Dvorak HF, Brown LF, Detmar M, Dvorak AM,. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146 (5): 1029-1039.
10. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD,. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87 (7): 1171-1180. (Pubitemid 27010101)
11. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD,. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277 (5322): 55-60. (Pubitemid 27450643)
12. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD,. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87 (7): 1161-1169. (Pubitemid 27010100)
13. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ,. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284 (5422): 1994-1998. (Pubitemid 29309448)
14. Lobov IB, Brooks PC, Lang RA,. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002; 99 (17): 11205-11210. (Pubitemid 34920903)
15. Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, Middleton M, Kato M, Ergun S, Schadendorf D,. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 2010; 207 (3): 491-503.
16. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E,. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103 (2): 159-165. (Pubitemid 29053133)
17. Franck-Lissbrant I, Haggstrom S, Damber JE, Bergh A,. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998; 139 (2): 451-456. (Pubitemid 28513188)
18. Stewart RJ, Panigrahy D, Flynn E, Folkman J,. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001; 165 (2): 688-693. (Pubitemid 32060501)
19. Haggstrom S, Wikstrom P, Bergh A, Damber JE,. Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Prostate 1998; 36 (2): 71-79. (Pubitemid 28311310)
20. Johansson A, Rudolfsson SH, Wikstrom P, Bergh A,. Altered levels of angiopoietin 1 and tie 2 are associated with androgen-regulated vascular regression and growth in the ventral prostate in adult mice and rats. Endocrinology 2005; 146 (8): 3463-3470. (Pubitemid 41058119)
21. Wang GM, Kovalenko B, Huang Y, Moscatelli D,. Vascular endothelial growth factor and angiopoietin are required for prostate regeneration. Prostate 2007; 67 (5): 485-499. (Pubitemid 46536942)
22. Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Biagini G,. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000; 45 (1): 72-79.
23. Aslan G, Cimen S, Yorukoglu K, Tuna B, Sonmez D, Mungan U, Celebi I,. Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer. Pathol Res Pract 2005; 201 (8-9): 593-598. (Pubitemid 41363954)
24. Strohmeyer D, Rossing C, Bauerfeind A, Kaufmann O, Schlechte H, Bartsch G, Loening S,. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000; 45 (3): 216-224.
25. West AF, O'Donnell M, Charlton RG, Neal DE, Leung HY,. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer 2001; 85 (4): 576-583. (Pubitemid 32808284)
26. Lind AJ, Wikstrom P, Granfors T, Egevad L, Stattin P, Bergh A,. Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate 2005; 62 (4): 394-399. (Pubitemid 40224144)
27. Tesan T, Gustavsson H, Welen K, Damber JE,. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models. BJU Int 2008; 102 (8): 1034-1039.
28. Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Bicknell R, Harris AL,. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int 2000; 85 (3): 276-280. (Pubitemid 30088518)
29. Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR,. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999; 54 (3): 523-527. (Pubitemid 29407032)
30. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL,. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997; 157 (6): 2329-2333. (Pubitemid 27208716)
31. Tanaka F, Ishikawa S, Yanagihara K, Miyahara R, Kawano Y, Li M, Otake Y, Wada H,. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 2002; 62 (23): 7124-7129. (Pubitemid 35424109)
32. Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, Koh GY, Tarnawski AS,. Overexpression of VEGF and angiopoietin 2: A key to high vascularity of hepatocellular carcinoma? Mod Pathol 2003; 16 (6): 552-557. (Pubitemid 36718436)
33. Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G,. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003; 63 (12): 3403-3412. (Pubitemid 36735901)
34. Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, Pablo L, McCoon P, Bedian V, Blakey DC,. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010; 9 (1): 145-156.
35. Hashizume H, Falcon BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV, Oliner JD, McDonald DM,. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70 (6): 2213-2223.
36. Welen K, Jennbacken K, Tesan T, Damber JE,. Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts. Prostate Cancer Prostatic Dis 2009; 12 (1): 41-46.
37. Kelly SH WK, Carducci MA, George DJ, Mahoney JF, Stadler WM, Morris MJ, Kantoff PW, Monk JP III., E. J. Small and Cancer and Leukemia Group B. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 9040. J Clin Oncol 2010; 28 (18S): LBA4511 (Meeting Abstract).
38. Haggstrom S, Stattin P, Wikstrom P, Bergh A, Damber JE,. Castration-induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer. BJU Int 2001; 88 (1): 110-116.
39. Johansson A, Rudolfsson SH, Kilter S, Bergh A,. Targeting castration-induced tumour hypoxia enhances the acute effects of castration therapy in a rat prostate cancer model. BJU Int 2010; 107 (11): 1818-1824.
40. Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, Gouvin LM, Sharma VM, Mercurio AM,. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: Implications for Gleason grading. Cancer Cell 2010; 17 (4): 319-332.
41. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA,. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007; 13 (23): 7003-7011. (Pubitemid 350276881)